Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 61
- Registration Number
- NCT00093483
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
- Conditions
- Myelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesLeukemia
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00093366
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
- Conditions
- LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- First Posted Date
- 2004-08-18
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Our Lady of Mercy Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00003885
- Locations
- 🇺🇸
Our Lady of Mercy Medical Center, Bronx, New York, United States
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
- Conditions
- LymphomaLeukemiaMultiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-08-16
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003395
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003630
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Stage II Multiple MyelomaStage III Multiple MyelomaRefractory Plasma Cell Neoplasm
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Oncotherapeutics
- Registration Number
- NCT00085345
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Hematology-Oncology Medical Group of Fresno, Incorporated, Fresno, California, United States
🇺🇸Utah Cancer Specialists - Administrative Office, Salt Lake City, Utah, United States
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Kidney Cancer
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005069
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
- Conditions
- LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 5
- Registration Number
- NCT00006220
- Locations
- 🇺🇸
Washington University Barnard Cancer Center, Saint Louis, Missouri, United States
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005040
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00081133
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.